GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » Net Income Including Noncontrolling Interests

Amgen (WBO:AMGN) Net Income Including Noncontrolling Interests : €3,842 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amgen Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Amgen's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2024 was €2,550 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 was €3,842 Mil.

Amgen Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Amgen's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Net Income Including Noncontrolling Interests Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,057.80 5,971.01 5,215.31 6,185.09 6,159.49

Amgen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,621.01 703.34 -103.96 693.03 2,549.83

Amgen Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,842 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Amgen's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
PFE BMY GILD MRK BIIB ABBV OGN AMRN SCLX MIRA LLY OCSE:NOVO B JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568
Traded in Other Exchanges
AMGN:USA AMG N:Mexico 1AMGN:Italy AMGd:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN:Chile AMGN34:Brazil AMGN:Argentina
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Website
https://www.amgen.com
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.